Sign In
Buy BAYRY
$13.89
-0.110 (-0.786%)
At Close: Jul 31, 2026
Here's Why the Maker of Roundup Weed Killer's Stock Is Surging Today
10:25am, Tuesday, 02'nd Dec 2025
Shares of pharmaceutical conglomerate Bayer (BAYRY) are surging 12% on their home exchange in Germany after the U.S. Solicitor General supported its efforts to have the Supreme Court review prior ruli
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
08:05am, Tuesday, 02'nd Dec 2025
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intraute
Bayer Crop Science Canada Launches EverGol Rise for Enhanced User Experience in Pulse Disease Control
06:00am, Tuesday, 02'nd Dec 2025
CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science Canada announced the launch of EverGol® Rise, setting a new standard in pulse disease control. Combining four different active ingredients, EverG
Bayer stock has its best day in 17 years after support from Trump's solicitor general
03:52am, Tuesday, 02'nd Dec 2025
Bayer shares rose as much as 15% on Tuesday after the U.S. solicitor general backed the company's bid to get the Supreme Court to curtail litigation alleging its Roundup pesticide causes cancer.
Trump administration backs Bayer's bid to curb Roundup lawsuits
07:35pm, Monday, 01'st Dec 2025
President Donald Trump's administration urged the U.S. Supreme Court on Monday to take up Bayer's bid to curtail thousands of lawsuits claiming its Roundup weedkiller causes cancer, backing the compan
Bayer Welcomes Solicitor General Support for U.S. Supreme Court Review
07:13pm, Monday, 01'st Dec 2025
LEVERKUSEN, Germany--(BUSINESS WIRE)--Bayer is pleased the Solicitor General supports U. S. Supreme Court review of the petition for a writ of certiorari in the Durnell case and agrees with the compan
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the
Here's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Value Stock
10:41am, Monday, 01'st Dec 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Market Today: Alphabet rallies, Amazon's $50B AI push
05:35pm, Monday, 24'th Nov 2025
Guru Stock PicksElfun Trusts has made the following transactions:Reduce in MLM by 7.18%Sold out in KVUEAdd in TXN by 36.84%New position in AMDStock News Tech-le
BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study
02:56pm, Monday, 24'th Nov 2025
Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major bleeding.
Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study
01:14pm, Monday, 24'th Nov 2025
Bayer AG (OTC: BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian.
Bayer stock jump 9% as stroke drug trial revives confidence in pipeline
05:01am, Monday, 24'th Nov 2025
Bayer shares surged on Monday after the company reported encouraging late-stage clinical trial results for its experimental cardiovascular drug asundexian, offering a rare boost for a pharmaceutical d
Bayer's stock is jumping on secondary stroke drug's trial success
04:47am, Monday, 24'th Nov 2025
Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals.
Bayer shares up more than 8% on revived fortunes for blood thinner
03:35am, Monday, 24'th Nov 2025
Shares in Bayer jumped more than 8% on Monday after initial clinical trial results turned around the fortunes of a key cardiovascular drug that suffered a major development setback two years ago.
Bayer Sees Positive Results in Study for Asundexian as Stroke Treatment
02:04am, Monday, 24'th Nov 2025
The pharma company said asundexian, when combined with antiplatelet therapy, lowered the risk of stroke in patients during the study.
